# Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

> **NCT05986734** · — · UNKNOWN · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 100 (estimated)

## Conditions studied

- Primary Immunodeficiency Diseases (PID)

## Interventions

- **DRUG:** Cutaquig

## Key facts

- **NCT ID:** NCT05986734
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986734, "Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05986734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*